Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine.

Dravet syndrome Lennox-Gastaut syndrome anti-seizure medication (ASM) fenfluramine pharmacoresistant epilepsy

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2022
Historique:
received: 05 12 2022
accepted: 21 12 2022
entrez: 23 1 2023
pubmed: 24 1 2023
medline: 24 1 2023
Statut: epublish

Résumé

[This corrects the article DOI: 10.3389/fphar.2022.832929.].

Identifiants

DOI: 10.3389/fphar.2022.1116575 PMID: 36686669 PMC: PMC9851158
pubmed: 36686669
doi: 10.3389/fphar.2022.1116575
pii: 1116575
pmc: PMC9851158
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

1116575

Commentaires et corrections

Type : ErratumFor

Informations de copyright

Copyright © 2023 Dini, Tulli, Dell’Isola, Mencaroni, Di Cara, Striano and Verrotti.

Auteurs

Gianluca Dini (G)

Department of Pediatrics, University of Perugia, Perugia, Italy.

Eleonora Tulli (E)

Department of Pediatrics, University of Perugia, Perugia, Italy.

Giovanni Battista Dell'Isola (GB)

Department of Pediatrics, University of Perugia, Perugia, Italy.

Elisabetta Mencaroni (E)

Department of Pediatrics, University of Perugia, Perugia, Italy.

Giuseppe Di Cara (G)

Department of Pediatrics, University of Perugia, Perugia, Italy.

Pasquale Striano (P)

Pediatric Neurology and Muscular Diseases Unit, IRCCS "G. Gaslini" Institute, Genoa, Italy.
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.

Alberto Verrotti (A)

Department of Pediatrics, University of Perugia, Perugia, Italy.

Classifications MeSH